公司简介
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...
关联新闻
- Novo Nordisk stock jumps as Wegovy pill sales beat estimates
Novo Nordisk shares NVO rallied on Wednesday after the Danish drugmaker reported stronger-than-expected third-quarter results, driven by demand for its Wegovy weight-loss pill, and raised its full-yea...
- GLP-1 drugs help control prediabetes better than current standard medicine
Today we feature a trio of interesting studies that will be presented in detail at the American Heart Association scientific sessions in Chicago this weekend.
- 2 Reasons for Hope From Novo Nordisk Earnings
The Danish drugmaker has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful.
- Beleaguered Novo offers relief to investors, thanks to Wegovy pill
Novo Nordisk stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss drug pill that was launched this year.
- Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S.
- Novo Nordisk's CFO Karsten Munk Knudsen to leave company
Novo Nordisk's CFO Karsten Munk Knudsen to leave company
- Novo raises full-year outlook as Wegovy sales impress
Novo raises full-year outlook as Wegovy sales impress
- Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
Novo Nordisk Q3 profit beats forecast; raises 2026 guidance